Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

This study is testing whether adding a cholesterol-lowering drug (atorvastatin) to a standard hormonal therapy (medroxyprogesterone acetate) can improve outcomes for young women with early-stage uterine cancer or abnormal uterine cell growth, while preserving their ability to have children. **You may be eligible if...** - You are a young woman diagnosed with early uterine lining cancer (Grade 1) or atypical uterine cell growth confirmed by biopsy - There is no sign the cancer has spread outside the uterus on imaging - You want to preserve your uterus or your ability to have children **You may NOT be eligible if...** - You are pregnant or may be pregnant - You have been diagnosed with another gynecologic cancer - You already take cholesterol-lowering medications - You have serious liver, kidney, or blood clotting problems - You have had a stroke, heart attack, or history of blood clots - You smoke heavily (more than 15 cigarettes per day) or drink heavily (more than 20g alcohol per day) Talk to your doctor to see if this trial is right for you.